| 期 |
栏目 |
标题 |
文件 |
| 卷 3, 编号 4 (2001) |
Articles |
Ftorafur - pervyy peroral'nyy ftorpirimidin v terapii metastaticheskogo kolorektal'nogo raka |
|
| 卷 3, 编号 4 (2001) |
Articles |
Novye immunologicheskie markery (CD71 , LU-BCRU-G7), vzaimosvyazannye s prognozom raka molochnoy zhelezy |
|
| 卷 10, 编号 1 (2008) |
Articles |
Ad\"yuvantnoe lechenie raka tolstoy kishki |
|
| 卷 11, 编号 3 (2009) |
Articles |
Mesto tsetuksimaba v terapii metastaticheskogo raka tolstoy kishki |
|
| 卷 11, 编号 4 (2009) |
Articles |
Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy |
|
| 卷 12, 编号 1 (2010) |
Articles |
Original'naya kombinatsiyaFtorafur® + vinorelbinv lechenii raka molochnoy zhelezy:pervye rezul'taty |
|
| 卷 12, 编号 2 (2010) |
Articles |
Mesto Taksotera v terapiimetastaticheskogo raka molochnoy zhelezy |
|
| 卷 12, 编号 3 (2010) |
Articles |
Panitumumab v terapii metastaticheskogokolorektal'nogo raka: dannye klinicheskikhissledovaniy, problema kozhnoy toksichnosti |
|
| 卷 13, 编号 2 (2011) |
Articles |
Rezhimy na osnove Taksotera®v terapii HER-2-pozitivnogo rakamolochnoy zhelezy |
|
| 卷 15, 编号 3 (2013) |
Articles |
Prolongirovannaya blokada angiogeneza pri metastaticheskom kolorektal'nom rake (novye dannye) |
|
| 卷 16, 编号 2 (2014) |
Articles |
Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board |
|
| 卷 19, 编号 1 (2017) |
Articles |
Albumin-bound paclitaxel in the treatment of metastatic breast cancer |
(Rus)
|
| 卷 13, 编号 3 (2011) |
Articles |
Kapetsitabin v terapiiantratsiklin- i taksanrezistentnogoraka molochnoy zhelezy |
|
| 卷 13, 编号 3 (2011) |
Articles |
Novye vozmozhnostiv lechenii raka pryamoy kishki |
|
| 卷 14, 编号 1 (2012) |
Articles |
Dotsetaksel v ad\"yuvantnoy terapiirannego raka molochnoy zhelezy bezporazheniya limfaticheskikh uzlov (N0) |
|
| 卷 14, 编号 3 (2012) |
Articles |
Podderzhivayushchaya terapiya pri metastaticheskom kolorektal'nom rake: odin iz variantov vybora ili novyy standart lecheniya? |
|
| 卷 14, 编号 4 (2012) |
Articles |
Ingibitory tirozinkinazy EGFR v terapii 1-y linii nemelkokletochnogo raka legkogo: perekhod ot empiricheskogo podkhoda k personalizatsii lecheniya |
|
